CoChat

Self-Monitoring of Blood Glucose as an Integral Part in the Management of People with Type 2 Diabetes Mellitus

Open access

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index; 14 of the 83 sources its claims cite were checked for support.

Abstract

For decades, self-monitoring of blood glucose (SMBG) has been considered a cornerstone of adequate diabetes management. Structured SMBG can follow different monitoring patterns, and it results in improved glycemic control, reduced hypoglycemia, and a better quality of life of people with diabetes. The technology, usability, and accuracy of SMBG systems have advanced markedly since their introduction a few decades ago. Current SMBG systems are small and easy to use, require small (capillary) blood sample volumes, and provide measurement results within seconds. In addition, devices are increasingly equipped with features such as connectivity to other devices and/or digital diaries and diabetes management tools. Although measurement quality can come close to or equal that of the glucose monitoring systems used by healthcare professionals, several available SMBG systems still do not meet internationally accepted accuracy standards, such as the International Organization for Standardization 15197 standard. Reports from China, India, and Brazil based on local experience suggest that in addition of the accuracy issues of SMBG systems, other obstacles also need to be overcome to optimize SMBG usage. Nonetheless, adequate usage of SMBG data is of high relevance for the management of people with type 2 diabetes mellitus.

Overview

CoChat Summary

TL;DR

This narrative review argues that self-monitoring of blood glucose (SMBG) remains an integral, beneficial component of type 2 diabetes management, especially when structured and actively used to guide therapy. It summarizes SMBG technology, accuracy standards, and local access/education barriers from China, India, and Brazil.

Key findings

  • Structured SMBG can improve glycemic control, reduce hypoglycemia, and improve quality of life; in non-insulin-treated T2DM, benefit is linked to actively using blood glucose values for treatment decisions or therapy adjustments.
  • Independent accuracy evaluations show many marketed SMBG systems still fail international standards: only 33% of evaluated systems met ISO 15197:2013 requirements in Klonoff et al., whereas 77% met them in Pleus et al.
  • Local reports show major access and adherence problems: China had 140 million adults with diabetes in 2021, prevalence rose from 10.9% in 2013 to 13.2% in 2020, and most (>70%) did not adhere to recommended SMBG frequency/timing; India had 74 million people with diabetes in 2021, projected to reach 92 million by 2030 and 124 million by 2045, with 80% paying out of pocket; Brazil had 15.7 million people with diabetes in 2021, with only 26% of public-system patients achieving HbA1c <7% versus 40% in private clinics.
  • Barriers include high out-of-pocket costs, insufficient self-management education and empowerment, limited access, and cultural beliefs; modern SMBG systems increasingly offer connectivity, digital diaries, reminders, and pattern analysis to support therapy.

Methods

  • Narrative review based on previously conducted studies; the authors state it contains no new studies with human participants or animals.
  • Synthesizes literature on SMBG systems, accuracy standards, diabetes management tools, and local experience reports from China, India, and Brazil.
  • No systematic review, meta-analysis, or primary data collection is described; the paper includes tables and figures illustrating structured testing profiles and accuracy plots.

Limitations

  • The paper states that it is based on previously conducted studies and does not contain new studies with human participants or animals.
  • The text does not report a systematic search strategy, inclusion/exclusion criteria, or formal risk-of-bias assessment; this is evident from the article format.
  • Some local data are described as unpublished or based on local experience, which may limit generalizability; this is evident from the India and local-experience sections.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s13300-022-01254-8

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 a Example of a structured glucose testing profile (7-point profile) using a system for self-monitoring of blood glucose (SMBG). SMBG results were entered manually into the ACCU-CHEK® 360° View Paper tool (Roche Diabetes Care GmbH, Mannheim, Germany), showing postprandial hyperglycemia. The forms for mmol/L and mg/dL can be downloaded from the Electronic Supplementary Material of this article. b Example of a glucose pattern analysis using an SMBG system. The figure shows the same glucose testing profile as in a, but data of the SMBG system were transferred to the RocheDiabetes Care Platform and visualized. RocheDiabetes, ACCU-CHEK and ACCU-CHEK 360° are trademarks of Roche
Fig. 1 a Example of a structured glucose testing profile (7-point profile) using a system for self-monitoring of blood glucose (SMBG). SMBG results were entered manually into the ACCU-CHEK® 360° View Paper tool (Roche Diabetes Care GmbH, Mannheim, Germany), showing postprandial hyperglycemia. The forms for mmol/L and mg/dL can be downloaded from the Electronic Supplementary Material of this article. b Example of a glucose pattern analysis using an SMBG system. The figure shows the same glucose testing profile as in a, but data of the SMBG system were transferred to the RocheDiabetes Care Platform and visualized. RocheDiabetes, ACCU-CHEK and ACCU-CHEK 360° are trademarks of RocheCC BY-NC · PubMed Central
Fig. 2 a Difference plot showing methods comparisons for two systems for SMBG with higher (green squares) and lower (red triangles) levels of accuracy. The orange lines reflect the accuracy requirements of the current ISO 15197:2015 standard [21], i.e., 95% of measurements need to fall within up to ± 0.8 mmol/L (± 15 mg/dL) or ± 15% from the comparison method (for values < 5.6 mmol/L [< 100 mg/dL] or ≥ 5.6 mmol/L [≥ 100 mg/dL]). b Scatter plot of SMBG systems with higher (green squares) and lower (red triangles) levels of accuracy
Fig. 2 a Difference plot showing methods comparisons for two systems for SMBG with higher (green squares) and lower (red triangles) levels of accuracy. The orange lines reflect the accuracy requirements of the current ISO 15197:2015 standard [21], i.e., 95% of measurements need to fall within up to ± 0.8 mmol/L (± 15 mg/dL) or ± 15% from the comparison method (for values < 5.6 mmol/L [< 100 mg/dL] or ≥ 5.6 mmol/L [≥ 100 mg/dL]). b Scatter plot of SMBG systems with higher (green squares) and lower (red triangles) levels of accuracyCC BY-NC · PubMed Central

Verification

Claims the paper makes

8 Valid · 2 Not valid · 51 Not checked · 47 Own results and interpretations

43 more claims · 2 with their cited sources checked

Create a free account to see all 108 claims and to verify the 69 references still open.

See all claims — free account
  • It may state two separate claims as one. 37
  • Probably not a substantial claim. 37

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 59 references

Research works printed but not linked: 3

  1. International Diabetes Federation. IDF diabetes atlas 10th edition 2021. 2021. https://diabetesatlas.org/data/en/. Accessed 09 Dec 2021.
  2. Chinese Diabetes Society. Guideline for clinical use of blood glucose monitoring (2015). Chin J Diabetes Mellitus. 2015;7:603–13.
  3. Indian Council of Medical Research. ICMR guidelines for management of type 2 diabetes. Delhi: Indian Council of Medical Research; 2018.

Cited by

See all 63

Metadata

Authors
Pleus, S., Freckmann, G., Schauer, S., Heinemann, L., Ziegler, R., Ji, L., Mohan, V., Calliari, L. E., & Hinzmann, R.
Affiliations
  • Universität Ulm (DE)
  • Peking University People's Hospital (CN)
  • Madras Diabetes Research Foundation (IN)
  • Roche Diabetes Care GmbH (Germany) (DE)
Corresponding author
Hinzmann, Rolf
Venue
Diabetes Therapy
Published
2022-04-13
Volume
13
Issue
5
Pages
829-846
ISSN
  • 1869-6953 (ISSN-L)
  • 1869-6961
OpenAlex
W4223596170
Cited by
55
References
59
Citations by year
2026: 13 · 2025: 18 · 2024: 14 · 2023: 10
FWCI
7.78
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetes Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Roche Diabetes Care GmbH
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
self-monitoring of blood glucose, type 2 diabetes, glycemic control, hypoglycemia, ISO 15197, digital health devices, diabetes management, quality of life

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Self-Monitoring of Blood Glucose as an Integral Part in the Management of People with Type 2 Diabetes Mellitus. https://app.cochat.ai/papers/10.1007/s13300-022-01254-8
The paper
Pleus, S., Freckmann, G., Schauer, S., Heinemann, L., Ziegler, R., Ji, L., Mohan, V., Calliari, L. E., & Hinzmann, R. (2022). Self-Monitoring of Blood Glucose as an Integral Part in the Management of People with Type 2 Diabetes Mellitus. Diabetes Therapy. https://doi.org/10.1007/s13300-022-01254-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.